Skip to content

Study · Non-randomized trial · n = 20 · 2002

2 results

Effect of the somatostatin analogue lanreotide on meal-stimulated portal blood flow in patients with liver cirrhosis.

Schiedermaier P, Harrison P, Arthur M, Grandt D, Sutton R, Drewe J, Larsen F, Sieber C

Digestion1 Jan 2002Cited by 5 (Europe PMC)

PMID11961344 (opens in a new tab)DOI10.1159/000051932 (opens in a new tab)PepBankPUB-11961344
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In cirrhosis, lanreotide blunted meal-stimulated portal blood flow versus placebo (AUC 45,237 +/- 2,507 versus 62,709.6 +/- 6,817 % x min, p < 0.05).

    In plain wordsIn cirrhosis, lanreotide reduced the meal-related rise in portal blood flow more than placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseMeal-stimulated portal blood flow
    Study

    n = 20

    Comparator
    placebo
    Outcome group
    Portal blood flow · Cardiovascular
    Studied dose
    100 microg/h · intravenous · 7 hAs given in this study (human).

    Measurements

    Meal-stimulated PVF increase (AUC), mean
    62709.6 % x min
    placebo (n=12)
    Meal-stimulated PVF increase (AUC), +/- value
    6817 % x min
    placebo (n=12)
    Meal-stimulated PVF increase (AUC), mean
    45,237 % x min
    lanreotide (n=8)
    Meal-stimulated PVF increase (AUC), +/- value
    2507 % x min
    lanreotide (n=8)
    p value
    < 0.05 none
    lanreotide vs placebo

    Source sentences

    Summary
    The meal-stimulated increase in PVF was blunted by lanreotide (AUC, % x min): 62,709.6 +/- 6,817 (placebo) vs. 45,237 +/- 2,507 (lanreotide), p < 0.05.
    2 context sentences
    Summary · context
    20 cirrhotic patients (placebo n = 12, lanreotide n = 8) with proven portal hypertension were studied after an overnight fast.
    Summary · context
    Lanreotide, at a dose of 100 microg/h, was infused intravenously over 7 h after a 1-hour basal period.
  2. 02HumanNon-randomized trialEfficacy outcome

    In cirrhosis, lanreotide blunted the postprandial heart rate increase during the first 2 h of meal perfusion versus placebo.

    In plain wordsIn cirrhosis, lanreotide reduced the meal-related heart rate increase during the first two hours compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreasePostprandial heart rate
    Study

    n = 20

    Comparator
    placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    100 microg/h · intravenous · 7 hAs given in this study (human).

    Source sentences

    Summary
    Lanreotide also blunted the postprandial increase in heart rate for the first 2 h of meal perfusion.
    2 context sentences
    Summary · context
    20 cirrhotic patients (placebo n = 12, lanreotide n = 8) with proven portal hypertension were studied after an overnight fast.
    Summary · context
    Lanreotide, at a dose of 100 microg/h, was infused intravenously over 7 h after a 1-hour basal period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.